Acute maxillary sinusitis

Upper respiratory tract Acute otitis media-Acute maxillary sinusitis Pharyngitis/Tonsillitis... 

Acute maxillary sinusitis 500 mg q24h lOto 14 days... 

Acute bacterial exacerbation of chronic bronchitis/community-acquired pneumonia/acute maxillary sinusitis/uncomplicated SSSI/chronic bacterial prostatitis... 

Levofloxacin (1), the levo-isomer or the (5)-enantiomer of ofloxacin, received FDA approval in 1996 (Fish, 2003 Hurst et al., 2002 Mascaretti, 2003 Norrby, 1999 North et al., 1998). The initial approval covered community-acquired pneumonia, acute bacterial exacerbation of chronic bronchitis, acute maxillary sinusitis, uncomplicated skin and skin structure infections, acute pyelonephritis, and complicated urinary tract infections (North et al., 1998). Four years later, the levofloxacin indication list grew to include community-acquired pneumonia caused by penicillin-resistant Streptococcus pneumoniae. In addition, in 2002, nosocomial (hospital-acquired) pneumonia caused by methicillin-susceptible Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Haemophilus influenzae, Kliebsella pneumoniae, and Escherichia coli was added (Hurst et al., 2002). Finally in 2004, LVX was approved as a post-exposure treatment for individuals exposed to Bacillus anthracis, the microbe that causes anthrax, via inhalation (FDA, 2004). 

Acute maxillary sinusitis PO 300 mg ql2h or600 mg q24hfor 10 days. 

Clarithromycin (250 mg bd for 10 days) was as effective as cefuroxime axetil (250 mg bd for 10 days) in the treatment of acute maxillary sinusitis in a randomized,... 

Stefansson P, J acovides A, Jablomcky P, Sedan S, Staley H. Cefuroxime axetil versus clarithromycin in the treatment of acute maxillary sinusitis. Rhinology 1998 36(4) 173-8. 

Williams JW Jr, Aguilar CCCC, Cornell J, et al. Antibiotics for acute maxillary sinusitis. Cochrane Rev 2003 3. 

Williams JW Jr, Holleman DR Jr, Samsa GP, et al. Randomized controlled trial of 3 vs 10 days of trimethoprim-sulfamethoxazole for acute maxillary sinusitis. JAMA 1995 273 1015-1021. 

Levofloxacin is a fluoroquinolone/ophthalmic/antibiotic that interferes with microbial DNA synthesis. It is indicated in the treatment of acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, nosocomial pneumonia, community-acquired pneumonia, skin and skin structure infections, chronic bacterial prostatitis, urinary tract infection (UTI), inhalational anthrax (postexposure), and acute pyelonephritis caused by susceptible strains of specific microorganisms. Ophthalmic use is for the treatment of conjunctivitis caused by susceptible strains of aerobic Gram-positive and aerobic Gram-negative microorganisms. 

Dubois, J., Saint-Pierre, C., and Tremblay, C. (1993). Efficacy of clarithromycin vs. amoxicil-lin/clavulanate in the treatment of acute maxillary sinusitis. Ear Nose Throat J. 72, 804-810. 

Haye, R., Lingaas, E., Hoivik, H. O., and Odegard, T. (1996). Efficacy and safety of azithromycin versus phenoxymethylpenicillin in the treatment of acute maxillary sinusitis. Eur. J. Clin. Microbiol. Infect. Dis. 15, 849-853. 

Trimethoprim-sulfamethoxazole is effective for acute exacerbations of chronic bronchitis. Administration of800-1200 mg sulfamethoxazole plus 160-240 mg trimethoprim twice a day appears to be effective in decreasing fever, purulence and volume of sputum, and sputum bacterial count. Trimethoprim-sulfamethoxazole should not be used to treat streptococcal pharyngitis because it does not eradicate the microorganism. It is effective for acute otitis media in children and acute maxillary sinusitis in adults caused by susceptible strains o/Haemophilus influenzae artd Streptococcus pneumoniae. 

---